natgillin/translations-raw huggingface dataset:
Cmin : ↓ 42%
Cmax : ↓ 13% Cmin : ↓ 42
Cmin : ↓ 51%
Cmax : ↓ 19% Cmin : ↓ 51
Cmin aften: ↑ 24% (↑ 3 til ↑ 50) b
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmin aften: ↑ 24% (↑ 3 til ↑ 50) Efavirenz:
Evening Cmin: ↑ 24% (↑ 3 to ↑ 50) Efavirenz:
Cmin aften: ↑ 24% (↑ 3 til ↑ 50)b Efavirenz:
Evening Cmin: ↑ 24 % (↑ 3 to ↑ 50)b Efavirenz:
Cmin morgen: ↑ 42% (↑ 9 til ↑ 86)
Morning Cmin: ↑ 42% (↑ 9 to ↑ 86)
Cmin ↑ 1,22 (0,86-1,74)
Cmin ↑ 1.22 (0.86-1.74)
Cmin ↑ 1,28 (1,13-1,45)
Cmin ↑ 1.28 (1.13-1.45)
Cmin ↓ 0,65 (0,56-0,74)
Cmin ↓ 0.65 (0.56-0.74)
Cmin ↓ 0,75 (0,61- 0,92)
Cmin ↓ 0.75 (0.61-0.92)
Cmin ↓ 0,76 (0,66-0,87)
Cmin ↓ 0.76 (0.66-0.87)
Cmin ↓ 0,78 (0,68-0,90)
Cmin ↓ 0.78 (0.68-0.90)
Cmin ↓ 0,78 (0,70-0,87)
Cmin ↓ 0.78 (0.70-0.87)
Cmin ↓ 0,82 (0,67-1,01)
Cmin ↓ 0.82 (0.67-1.01)
Cmin ↔ 0,89 (0,81-0,98)
Cmin ↔ 0.89 (0.81-0.98)
Cmin ↔ 0,97 (0,83-1,15)
Cmin ↔ 0.97 (0.83-1.15)
Cmin ↔ 1,08 (1,04-1,14)
Cmin ↔ 1.08 (1.04-1.14)
Cmin ↔ 1,09 (1,01-1,18)
Cmin ↔ 1.09 (1.01-1.18)
Cmin ↔ 1,10 (1,02-1,19)
Cmin ↔ 1.10 (1.02-1.19)
Cmin  0,91 (0,84-0,98)
Cmin ↔ 0.91 (0.84-0.98)
Cmin  1,23 (0,87-1,75)
Cmin ↑ 1.23 (0.87-1.75)
Cmin 19 % (-42 % til +13 %)
Cmin  19% (-42%; +13%)
Cmin 33 % (-50 % til -10 %)
Cmin  33% (-50%; -10%)
Cmin 54 % (-74 % til -18 %)
Cmin  54 % (-74%; -18%)
Cmin*: 0,41 (0,34; 0,50)
Cmin*: 0.41 (0.34, 0.50)
Cmin-værdierne for enzalutamid og dets aktive metabolit hos individuelle patienter ved steady- state forblev konstante gennem mere end et års kronisk behandling, hvilket viser, at der er tidslineær farmakokinetik, når steady-state er opnået.
The steady-state Cmin values of enzalutamide and the active metabolite in individual patients remained constant during more than one year of chronic therapy, demonstrating time-linear pharmacokinetics once steady-state is achieved.
Cmin. ↑ 1,23 (0,87-1,75)
Cmin ↑ 1.23 (0.87-1.75)
Cmin. ↑ 1,52 (1,41-1,64)
Cmin ↑ 1.52 (1.41-1.64)
Cmin.  1,52 (1,41-1,64)
Cmin ↑ 1.52 (1.41-1.64)
Cmin.  2,09 (1,90-2,31)
Cmin ↑ 2.09 (1.90-2.31)
Cmin: 0,89 (0,75; 1,06)
Cmin: 0.89 (0.75, 1.06)
Cmin: 1,17 (1,03; 1,32)
Cmin: 1.17 (1.03, 1.32)
Cmin: 1,46 (1,12; 1,89)
Cmin: 1.46 (1.12, 1.89)
Cmin: 2,68 (2,42 ; 2,98)
Cmin: 2.68 (2.42, 2.98)
Cmin: I/R Cmax: ↑ 2 %
Cmin: N/A Cmax: ↑ 2
Cmin: I/R Cmax: ↑ 21 %
Cmin: N/A Cmax: ↑ 21
Cmin: I/R Cmax: ↓ 1 %
Cmin: N/A Cmax: ↓ 1
Cmin: I/R Cmax: ↓ 14 %
Cmin: N/A Cmax: ↓ 14
Cmin: I/R Cmax: ↓ 85 %
Cmin: N/A Cmax: ↓ 85
Cmin: I/R Cmax: ↔
Cmin: N/A Cmax: ↔
Cmin: IB
NC = not calculated.
Cmin: ikke bestemt
Cmin: not determined
Cmin: ikke vurderet Cmax: ↑ 21%
Cmin: NA Cmax: ↑ 21
Cmin: ikke vurderet Cmax: ↓ 14%
Cmin: NA Cmax: ↓ 14
Cmin: ikke vurderet Cmax: ↓ 85%
Cmin: NA Cmax: ↓ 85
Cmin: ikke vurderet Cmax: ↔
Cmin: NA Cmax: ↔
Cmin: ↑ 118% (↑ 91 til ↑ 150)
Cmin: ↑ 118% (↑ 91 to ↑ 150)
Cmin: ↑ 13% (↑ 1 til ↑ 26) (CYP3A4-induktion)
Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction)
Cmin: ↑ 14,4 gange
Cmin: ↑ 14.4-fold
Cmin: ↑ 14,4 gange
Fluvastatin or
Cmin: ↑ 163% (↑ 137 til ↑ 197)
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Cmin: ↑ 25% (↑ 7 til ↑ 46) (hæmning af CYP-medieret oxidativ metabolisme)
Cmin: ↑ 25% (↑ 7 to ↑ 46) (inhibition of CYP-mediated oxidative metabolism)
Cmin: ↑ 3.5-fold Cmax: ↓ (I forhold til 800 mg tre gange daglig alene)
Cmin: ↑ 3.5-fold Cmax: ↓ (relative to indinavir 800 mg TID
Cmin: ↑ 3.5-fold Cmax: ↓ (I forhold til 800 mg tre gange daglig alene)
Cmin: ↑ 3.5-fold Cmax: ↓ (relative to indinavir 800 mg TID alone)
Cmin: ↑ 45% (↑ 27 til ↑ 64)
Cmax: ↑ 64% (↑ 54 – ↑ 74)
Cmin: ↑ 47% (↑ 38 til ↑ 57)
Cmin: ↑ 47% (↑ 38 to ↑ 57)
Cmin: ↑ 59% (↑ 49 til ↑ 70)
Cmin: ↑ 59% (↑ 49 to ↑ 70)
Cmin: ↑ 63% (↑ 45 til ↑ 84)
Cmin: ↑ 48% (↑ 34 – ↑ 63)
Cmin: ↑ 67 %
Cmin: ↑ 67
Cmin: ↓ 10% (↑ 1 til ↓ 19) (CYP3A-induktion forårsaget af efavirenz)
Cmin: ↓ 10% (↑ 1 to ↓ 19)% (CYP3A induction by efavirenz)
Cmin: ↓ 10% (↑ 1 til ↓ 19) (efavirenzudløst CYP3A-induktion)
Cmin: ↓ 10% (↑ 1 to ↓ 19) (CYP3A induction by efavirenz)
Cmin: ↓ 12 % (↓ 24 til ↑ 1) (CYP3A4-induktion)
Cmin: ↓ 12 % (↓ 24 to ↑ 1)
Cmin: ↓ 12% (↓ 24 til ↑ 1)
Cmin: ↓ 12 % (↓ 24 to ↑ 1)
Cmin: ↓ 12% (↓ 24 til ↑ 1) (CYP3A4-induktion)
Cmin: ↓ 12 % (↓ 24 to ↑ 1)
Cmin: ↓ 15% (↓ 12 til ↓ 9)
Cmin: ↓ 15% (↓ 12 to ↓ 9)
Cmin: ↓ 2% (↓ 9 til ↑ 6)
Cmin: ↓ 2% (↓ 9 to ↑ 6)
Cmin: ↓ 25% (↓ 14 til ↓ 34)
Cmin: ↓ 25% (↓ 14 to ↓ 34)% Efavirenz:
Cmin: ↓ 25% (↓ 14 til ↓ 34) Efavirenz:
Cmin: ↓ 25% (↓ 14 to ↓ 34) Efavirenz:
Cmin: ↓ 25% (↓ 14 til ↓ 34) Efavirenz:
Cmin: ↓ 25% (↓ 14 to ↓ 34)% Efavirenz:
Cmin: ↓ 26% (↓ 46 - ↑ 10)
Cmin: ↓ 26% (↓ 46 – ↑ 10)
Cmin: ↓ 26% (↓ 46 til ↑ 10)
Cmin: ↓ 26% (↓ 46 to ↑ 10)
Cmin: ↓ 32% (↓ 15 til ↓ 46)
Cmax: 0 32% (0 15 to 0 46)
Cmin: ↓ 32% (↓ 15 til ↓ 46)
Cmax: ↑ 16% (↑ 2 to ↑ 32)
Cmin: ↓ 32% (↓ 15 til ↓ 46)
Cmin: ↓ 32 % (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15 til ↓ 46) (CYP3A4- og CYP2B6-induktion)
Cmin: ↓ 32 % (↓ 15 to ↓ 46)
Cmin: ↓ 32% (↓ 15 til ↓ 46) (CYP3A4- og CYP2B6-induktion)
Cmin: ↓ 32% (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 34% (↓ 43 til ↑ 24)
Cmin: ↓ 34% (↓ 43 to ↑ 24)
Cmin: ↓ 34% (↓ 43 til ↑ 24) Sofosbuvir:
Cmin: ↓ 34% (↓ 43 to ↑ 24) Sofosbuvir:
Cmin: ↓ 35% (↓ 24 til ↓ 44)
Cmin: 0 35% (0 24 to 0 44)
Cmin: ↓ 35% (↓ 24 til ↓ 44) Efavirenz:
Cmin: ↓ 35 % (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 35% (↓ 24 til ↓ 44) Efavirenz:
Cmin: ↓ 35% (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 37% (↓ 17 til ↓ 52)
Cmin: 0 37% (0 17 to 0 52)
Cmin: ↓ 37% (↓ 17 til ↓ 52) Efavirenz:
Cmin: ↓ 37 % (↓ 17 to ↓ 52) Efavirenz:
Cmin: ↓ 37% (↓ 17 til ↓ 52) Efavirenz:
Cmin: ↓ 37% (↓ 17 to ↓ 52) Efavirenz:
Cmin: ↓ 40 %
Cmin: j 17
Cmin: ↓ 42%* (↓ 31 til ↓ 51)
Cmax: ↑ 17%* (↑ 8 to ↑ 27) Cmin: ↓ 42%* (↓ 31 to ↓ 51)
Cmin: ↓ 43 % (↓ 18 til ↓ 60)
Cmin: ↓ 43 % (↓ 18 to ↓ 60)
Cmin: ↓ 43% (↓ 18 til ↓ 60)
Cmin: ↓ 43 % (↓ 18 to ↓ 60)
Cmin: ↓ 43% (↓ 18 til ↓ 60) Efavirenz:
Cmin: ↓ 43% (↓ 18 to ↓ 60) Efavirenz:
Cmin: ↓ 44 % (↓ 27 til ↓ 58)
Cmin: ↓ 35% (↓ 24 to ↓ 44)
Cmin: ↓ 44 % (↓ 27 til ↓ 58)
Cmin: ↓ 44 % (↓ 27 to ↓ 58)
Cmin: ↓ 44% (↓ 27 til ↓ 58)
Cmin: ↓ 44 % (↓ 27 to ↓ 58)
Cmin: ↓ 44% (↓ 27 til ↓ 58) (fald i itraconazolkoncentrationerne: CYP3A4-induktion) Hydroxyitraconazol:
Cmin: ↓ 44% (↓ 27 to ↓ 58) (decrease in itraconazole concentrations: CYP3A4 induction) Hydroxyitraconazole:
Cmin: ↓ 45% (↓ 31 til ↓ 56) Efavirenz:
Cmin: ↓ 45% (↓ 31 to ↓ 56) Efavirenz:
Cmin: ↓ 46% (↓ 31 til ↓ 58)
Cmin: 0 46% (0 31 to 0 58)
Cmin: ↓ 46% (↓ 31 til ↓ 58) Efavirenz:
Cmin: 0 46% (0 31 to 0 58)
Cmin: ↓ 46% (↓ 31 til ↓ 58) Efavirenz:
Cmin: ↓ 46 % (↓ 31 to ↓ 58) Efavirenz:
Cmin: ↓ 46% (↓ 31 til ↓ 58) Efavirenz:
Cmin: ↓ 46% (↓ 31 to ↓ 58) Efavirenz:
Cmin: ↓ 47% (↓ 41 til ↓ 53) (fald i carbamazepin- koncentrationen: CYP3A4- induktion; fald i efavirenz- koncentrationen: CYP3A4- og CYP2B6-induktion).
Cmin: ↓ 47 % (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41 til ↓ 53) (fald i carbamazepin-koncentrationen: CYP3A4-induktion; fald i efavirenz- koncentrationen: CYP3A4- og CYP2B6- induktion).
Cmin: ↓ 47 % (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41 til ↓ 53) (fald i carbamazepinkoncen-trationer: CYP3A4-induktion; fald i efavirenzkoncentrationer: CYP3A4- CYP2B6-induktion)
Cmin: ↓ 47% (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 50 % (↓ 40 til ↓ 59)b Efavirenz:
Cmin: 0 50% (0 40 to 0 59)b Efavirenz:
Cmin: ↓ 62% (↓ 44 til ↓ 75)
Cmin: 0 62% (0 44 to 0 75)
Cmin: ↓ 62% (↓ 44 til ↓ 75)
Cmin: ↓ 62% (↓ 44 to ↓ 75)
Cmin: ↓ 63% (↓ 44 til ↓ 75)
Cmin: 0 63% (0 44 to 0 75)
Cmin: ↓ 63% (↓ 44 til ↓ 75)
Cmin: ↓ 63 % (↓ 44 to ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 63% (↓ 44 til ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 63 % (↓ 44 to ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 63% (↓ 44 til ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 63% (↓ 44 to ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 8% (↑ 14 til ↓ 25) Norelgestromin (aktiv metabolit): AUC: ↓ 64% (↓ 62 til ↓ 67)
Cmin: 0 8% (j 14 to 0 25) Norelgestromin (active metabolite): AUC: 0 64% (0 62 to 0 67)
Cmin: ↓ 8% (↑ 14 til ↓ 25) Norelgestromin (aktiv metabolit): AUC: ↓ 64% (↓ 62 til ↓ 67)
Cmin: ↓ 8% (↑ 14 to ↓ 25) Norelgestromin (active metabolite): AUC: ↓ 64% (↓ 62 to ↓ 67)
Cmin: ↓ 82% (↓ 79 til ↓ 85)
Cmin: 0 82% (0 79 to 0 85)
Cmin: ↓ 82% (↓ 79 til ↓ 85) Levonorgestrel (aktiv metabolit): AUC: ↓ 83% (↓ 79 til ↓ 87)
Cmin: ↓ 82 % (↓ 79 to ↓ 85) Levonorgestrel (active metabolite): AUC: ↓ 83 % (↓ 79 to ↓ 87)
Cmin: ↓ 82% (↓ 79 til ↓ 85) Levonorgestrel (aktiv metabolit): AUC: ↓ 83% (↓ 79 til ↓ 87)
Cmin: ↓ 82% (↓ 79 to ↓ 85) Levonorgestrel (active metabolite): AUC: ↓ 83% (↓ 79 to ↓ 87)
Cmin: ↓ 86% (↓ 80 til ↓ 90) (induktion af metabolisme) Efavirenz: ingen klinisk signifikant interaktion.
Cmin: ↓ 86% (↓ 80 to ↓ 90) (induction of metabolism) Efavirenz: no clinically significant interaction.
Cmin: ↓ 91% (↓ 88 til ↓ 92) Efavirenz:
Cmin: ↓ 91% (↓ 88 to ↓ 92) Efavirenz:
Cmin: ↔
Antimycobacterials
Cmin: ↔ (CYP3A4-induktion)
Cmin: ↔ (CYP3A4 induction)
Cmin:  17 % Cmax:  15 % (CYP3A4-hæmning)
Cmin: ↑ 17 % Cmax: ↑ 15% (CYP3A4 inhibition)
Cmin:  42 %* ( 31 til  51)
Cmax: j17%* (j8 to j27) Cmin: 042%* (031 to 051)
Cmin:  42 %* ( 31 til  51)
Cmin: ↓ 42 %* (↓ 31 to ↓ 51)
CML
CML;
CML er en leukæmi, hvor granulocytterne (en form for hvide blodlegemer) begynder at vokse ukontrolleret.
CML is a leukaemia where granulocytes (a type of white blood cell) start growing out of control.
CML i "kroniske", "accelererede" og "blast" faser.
CML in ‘chronic’, ‘accelerated’ and ‘blast’ phases.
CML i accelereret fase
Accelerated Phase CML
CML i accelereret fase og blastkrise og Ph+ALL (startdosis 600 mg)
(starting dose 600 mg)
CML i blastkrise og
CML in blast crisis and
CML i fremskreden fase
Accelerated phase CML
CML i kronisk fase (startdosis 100 mg 1 gang dagligt)
Chronic phase CML (starting dose 100 mg once daily)
CML i kronisk fase efter fejlslagen interferonalpha-behandling eller i accelereret fase.
CML in the chronic phase after failure of interferon-alpha therapy, or in the accelerated phase.
CML i kronisk fase – nyligt diagnosticeret
Chronic phase CML - Newly diagnosed
CML i kronisk fase – resistens eller intolerans over for tidligere imatinib-behandling
Chronic phase CML - Resistance or intolerance to prior imatinib therapy
CML i kronisk fase, MDS/MPD (startdosis 400 mg)
Chronic phase CML, MDS/MPD (starting dose 400 mg)
CML- CML-AP
CML- CML
CMV-nethindebetændelse, men kan forbedre din tilstand ved at forsinke sygdommens udvikling.
Vistide will not cure CMV retinitis but may improve your condition by delaying progression of the disease.
CNS-blødning*b, synkope, tremor, amnesi, balanceforstyrrelser
CNS bleeding*b, syncope, tremor, amnesia, balance disorder
CNS-demyeliniseringstilfælde som antyder multipel sclerose eller lokaliserede demyeliniseringsforhold som for eksempel opticus neuritis og transversel myelitis (se pkt 4.4)
CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions, such as optic neuritis and transverse myelitis (see section 4.4)
CNS-demyeliniseringstilfælde som antyder multipel sklerose eller lokaliserede demyeliniseringsforhold som for eksempel opticusneuritis og transversel myelitis (se pkt 4.4)
CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions, such as optic neuritis and transverse myelitis (see section 4.4)
CNS-demyeliniseringstilfælde som antyder multipel sklerose eller lokaliserede demyeliniseringsforhold som for eksempel opticusneuritis og transversel myelitis (sepkt 4.4)
CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions such as optic neuritis and transverse myelitis (see section 4.4)
CNS-depression
CNS depression
CNS-LS-score går fra en mindsteværdi på 7 (ingen symptomer) til en maksimumværdi på 35.
CNS-LS scores range from a minimum of 7 (no symptoms) to a maximum of 35.
CNS-lægemidler: Bortset fra de her i afsnittet nævnte interaktioner, er risikoen ved brug af duloxetin i kombination med andre CNS-aktive lægemidler ikke blevet systematisk undersøgt.
CNS medicinal products: The risk of using duloxetine in combination with other CNS-active medicinal products has not been systematically evaluated, except in the cases described in this section.
CNS-toksicitet kendes ikke.
CNS toxicity have not been established.
CNS-TUMORER
CNS TUMOURS
Co Meath
IRL-Co Meath
Co Wicklow Irland
Co Wicklow Ireland
co-administereret med lavdosis ritonavir kan forventes at øge plasmakoncentrationen af calcium- antagonisterne.
with low dose ritonavir can be expected to
Co-administration
Co-administration of
co-administration
Tacrolimus
Co-administration af
Therefore, co-administration of
Co-administration af atorvastatin
Co-administration of atorvastatin and
co-administration af boostet
recommended when
Co-administration af boostet PREZISTA med disse antikoagulantia kan øge koncentrationerne af antikoagulanset.
Co-administration of boosted PREZISTA with these anticoagulants may increase concentrations of the anticoagulant.
Co-administration af darifenacin 7,5 mg og den potente CYP3A4 hæmmer ketoconazol 400 mg, resulterede i 5 gange så høj AUC for darifenacin ved steady- state.
Co-administration of darifenacin 7.5 mg with the potent CYP3A4 inhibitor ketoconazole 400 mg resulted in a 5-fold increase in steady-state darifenacin AUC.
Co-administration af darunavir og ritonavir med lægemidler, der især metaboliseres af CYP3A og/eller CYP2D6 eller transporteres af P- gp, kan forårsage øget systemisk eksponering for sådanne lægemidler, hvilket kan øge eller forlænge både den terapeutiske virkning og bivirkninger.
Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Co-administration af darunavir og ritonavir og andre lægemidler, der hæmmer CYP3A, kan nedsætte clearance af darunavir og ritonavir og kan medføre øgede plasmakoncentrationer af darunavir og ritonavir (f.eks. indinavir, systemiske azoler som ketoconazol og clotrimazol).
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, systemic azoles like ketoconazole and clotrimazole).
Co-administration af darunavir og ritonavir og lægemidler, som primært metaboliseres af CYP2D6 (såsom flecainid, propafenon, metoprolol), kan resultere i en øget plasmakoncentration af disse lægemidler, hvilket kan øge eller forlænge deres terapeutiske effekt og bivirkninger.
Co-administration of darunavir and ritonavir and medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Co-administration af darunavir/cobicistat med svage til moderate CYP3A-induktorer (f.eks. efavirenz, etravirin, nevirapin, boceprevir, telaprevir, fluticason og bosentan) frarådes (se interaktionstabel nedenfor).
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, nevirapine, boceprevir, telaprevir, fluticasone, and bosentan) is not recommended (see interaction table below).
Co-administration af darunavir/cobicistat med svage til moderate CYP3A-induktorer (f.eks. efavirenz, etravirin, nevirapin, boceprevir, telaprevir, fluticason og bosentan) kan ikke anbefales (se interaktionstabel nedenfor).
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, nevirapine, boceprevir, telaprevir, fluticasone, and bosentan) is not recommended (see interaction table below).
Co-administration af darunavir/ritonavir med lægemidler, der især metaboliseres af CYP3A og CYP2D6 eller transporteres af P-gp, kan forårsage øget systemisk eksponering for sådanne lægemidler, hvilket kan øge eller forlænge både den terapeutiske virkning og bivirkninger.
Co-administration of darunavir/ritonavir with medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Co-administration af ketoconazol 200 mg 2 gange daglig, en stærk hæmmer af CYP3A4, forårsagede en stigning i cinacalcet-niveauerne til ca. det dobbelte.
Co-administration of 200 mg, twice daily ketoconazole, a strong inhibitor of CYP3A4, caused an approximate 2-fold increase in cinacalcet levels.
Co-administration af parenteral midazolam
If parenteral midazolam is co-administered
Co-administration af potente CYP3A4/2C9-hæmmere til patienter med nedsat CYP2D6-metabolisme kan potentielt resultere i højere eksponering (se pkt.
Co-administration of strong CYP3A4/2C9 inhibitors to CYP2D6 poor metabolisers could potentially result in higher exposure (see section 4.5).
co-administration af PREZISTA
co-administration of PREZISTA
co-administration af PREZISTA
Concomitant use of PREZISTA
co-administration af PREZISTA
recommended when
Co-administration af PREZISTA co-administreret med cobicistat og bosentan frarådes.
Co administration of PREZISTA co-administered with cobicistat and bosentan is not recommended.
Co-administration af saxagliptin og metformin er blevet undersøgt hos patienter med type 2-diabetes, som var utilstrækkeligt kontrolleret på metformin alene, og hos behandlingsnaive patienter, der var utilstrækkeligt kontrolleret på diæt og motion alene.
The co-administration of saxagliptin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone.
Co-administration af saxagliptin og metformin er blevet undersøgt hos patienter med type 2-diabetes, som var utilstrækkeligt kontrolleret på metformin alene, og hos behandlingsnaive patienter, der var utilstrækkeligt kontrolleret på diæt og motion alene.
The coadministration of saxagliptin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone.
Co-administration af tadalafil til
Co-administration of tadalafil for
co-administration bør den daglige dosis af ketoconazol ikke overskride 200 mg.
the daily dose of ketoconazole should not exceed 200 mg.
co-administration foretages
immunosuppressive agent must be
Co-administration med
Co-administration with
co-administration med boostet
co-administered with boosted
Co-administration med boostet PREZISTA kan medføre en markant stigning i eksponeringen for ticagrelor.
Co-administration with boosted PREZISTA may lead to a substantial increase in exposure to ticagrelor.
Co-administration med dabigatran
Co-administration with dabigatran
Co-administration med darunavir boostet med lavdosis ritonavir kan medføre en markant stigning i eksponeringen for ticagrelor.
Co-administration with darunavir boosted with low dose ritonavir may lead to a substantial increase in exposure to ticagrelor
Co-administration med potente CYP3A4-inhibitorer såsom ketoconazol, itraconazol, voriconazol, posaconazol, telithromycin, clarithromycin, nefazodon og ritonavir (se pkt.
Co-administration with potent cytochrome P 450 (CYP) 3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir (see section 4.5)
Co-administration sammen med transportsubstrater/hæmmere
Co-administration with transport substrates/inhibitors
Co-administrationen af docetaxel, doxorubicin og cyclophosfamid påvirkede ikke deres farmakokinetik.
The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co- administration.
co-administrere PREZISTA med
co-administer PREZISTA with low
Co-administrerede lægemidlers virkning på decitabin
Impact of co-administered medicinal products on decitabine
co-administreret med ritonavir (600/100 mg to gange dagligt) efter genotype ved baselinea og baseline darunavir FC ved baseline og efter brug af enfuvirtid (ENF): Som behandlede resultater fra POWER- og DUET-studierne.
darunavir FC and by use of enfuvirtide (ENF): As treated analysis of the POWER and DUET trials.
CO-bekræftet afholdenhed i løbet af uge 9 til og med 12 og 9 til og med 24 sammenlignet med forsøgspersoner, der blev behandlet med bupropion, nikotinplaster og placebo (se nedenstående tabel).
CO-confirmed abstinence during weeks 9 through 12 and 9 through 24 compared to subjects treated with bupropion, nicotine patch and placebo (please see table below).
Co-infektion med HBV (hepatitis B-virus) eller HCV (hepatitis C-virus)
Co-infection with HBV (hepatitis B virus) or HCV (hepatitis C virus)
Co-inficerede patienter med fremskreden cirrose, der får HAART, kan have øget risiko for nedsat leverfunktion og død.
Co-infected patients with advanced cirrhosis receiving HAART may be at increased risk of hepatic decompensation and death.
Co-inficerede patienter med fremskreden cirrose, der modtager kombineret antiretroviral terapi (cART), kan have øget risiko for leverdekompensation og død.
Co-infected patients with advanced cirrhosis receiving combined anti-retroviral therapy (cART) may be at increased risk of hepatic decompensation and death.
Co-inficerede patienter med fremskreden leversygdom, der modtager cART, kan have øget risiko for forværring af leverfunktionen.
Co-infected patients with advanced liver disease receiving cART may be at increased risk of worsening liver function.
Co-inficerede patienter med fremskreden leversygdom, der tager (HAART), kan have øget risiko for forværring af leverfunktionen.
Co-infected patients with advanced liver disease receiving (HAART) may be at increased risk of worsening liver function.
Co-inficerede patienter med fremskreden leversygdom, der tager HAART, kan have øget risiko for forværring af leverfunktionen.
Co-infected patients with advanced liver disease receiving HAART may be at increased risk of worsening liver function.
Co-primære endepunkter: ARR og SAD.
Co-primary endpoints: ARR & SAD.
CoA-reduktasehæmmere.
inhibitors may be necessary.
Coagadex 250 ie
coagadex 250 iu
Coagadex 500 IE
Coagadex 500 IU
Coagadex blev vurderet som udmærket til alle kirurgiske procedurer (ingen postoperativ blødning, intet behov for blodtransfusioner, og blodtab var ikke mere end 'som forventet) til at kontrollere blodtab under og efter operationen.
For all surgical procedures, Coagadex was assessed as excellent (no post-operative bleeding, no requirement of blood transfusions, and blood loss was no more than ‘as expected’) in controlling blood loss during and after surgery.
Coagadex er et koncentrat af human koagulationsfaktor X – et protein, der kræves for at blod kan størkne.
Coagadex is a concentrate of human coagulation factor X, a protein that is needed for blood to clot.
Coagadex er undersøgt i ét hovedstudie, hvori der deltog 16 patienter med faktor X-mangel i alderen 12-42 år.
Coagadex has been investigated in one main study involving 16 patients with factor X deficiency aged 12 to 42 years.
Coagadex fås som et pulver og en opløsningsvæske (en solvens), som bruges til at fremstille en opløsning, der gives som indsprøjtning i en blodåre.
Coagadex is available as a powder and solvent used to make a solution for injection into a vein.
Coagadex indeholder det aktive stof human koagulationsfaktor X.
Coagadex contains the active substance human coagulation factor X.
Coagadex må derfor kun anvendes under amning, hvis det er klart indiceret.
Therefore, Coagadex should be used during breast- feeding only if clearly indicated.
Coagadexs sikkerhed og virkning hos børn under 12 år er endnu ikke klarlagt.
The safety and efficacy of Coagadex in children less than 12 years of age have not yet been established.
Coagulase negative stafylokokker
Coagulase negative staphylococci
Coagulase positive Staphylococcus spp.3,4
Coagulase positive